KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.

Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John R Zalcberg, Robin L Jones, Yoon-Koo Kang, Albiruni Abdul Razak, Jonathan Trent, Steven Attia, Axel Le Cesne, Kjetil Boye, David Goldstein, César Sánchez, Brittany L Siontis, Paulina Cox, Erika Davis, Matthew L Sherman, Rodrigo Ruiz-Soto, Sebastian Bauer

J Clin Oncol 43(20) 2239-2244

PMID40408605
PMCIDPMC12225728
DOI10.1200/JCO-24-02818
发表日期2025-05-23
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

In the INTRIGUE phase III trial (ClinicalTrials.gov identifier: NCT03673501), adult patients with advanced gastrointestinal stromal tumor previously treated with imatinib were randomly assigned 1:1 to ripretinib 150 mg once daily or sunitinib 50 mg once daily (4 weeks on/2 weeks off). In the primary analysis, overall survival (OS) was immature. In this study, we report the final planned analysis of OS (key secondary end point), progression-free survival (PFS) on third-line therapy (second PFS; prespecified exploratory end point), and long-term safety. Final OS analysis was prespecified to occur with approximately 200 and ≥145 events in the overall and KIT exon 11 intention-to-treat (ITT) populations, respectively. As of March 15, 2023, there were 211 and 151 OS events in the overall ITT and KIT exon 11 ITT populations, respectively. Median OS was similar between second-line ripretinib and sunitinib in both populations (overall, 35.5 v 31.5 months; KIT exon 11, 35.5 v 32.8 months). Median second PFS (on third-line therapy) for the overall ITT population was similar between the ripretinib and sunitinib arms (7.7 v 7.4 months). Safety was consistent with the primary analysis. OS from this analysis was similar between arms, and second PFS suggests that receiving ripretinib did not adversely affect the PFS of third-line therapy.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG A2.

Second PFS for patients in the (A) KIT exon 11 ITT population who received any third-line treatment or (B) the most common third-line treatment by random treatment assignment. Second PFS was defined as the time interval between the date of the first nonprotocol follow-up drug therapy and the disease progression on this drug therapy based on the local assessment or death due to any cause, whichever came first. Third-line treatment was chosen by site physicians after discontinuation of random assignment. HR, hazard ratio; ITT, intention-to-treat; PFS, progression-free survival.

A

PFS

FIG A2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

FIG A2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.Final OS in the (A) overall ITT and (B) KIT exon 11 ITT populations and (C) second PFS for patients in the overall ITT population who received any third-line therapy or (D) the most common third-line therapy by random treatment assignment. Second PFS was defined as the time interval between the date of the first nonprotocol drug therapy and disease progression on this drug therapy based on local assessment or death due to any cause, whichever came first. Third-line treatment was chosen by site physicians after discontinuation of random assignment. HR, hazard ratio; ITT, intention-to-treat; NE, not estimable; OS, overall survival; PFS, progression-free survival.
非 KM Figure
FIG A1.CONSORT diagram. AE, adverse event; IRR, independent radiologic review; ITT, intention-to-treat; PD, progressive disease.
非 KM Figure